Results 261 to 270 of about 254,702 (346)

Cardiovascular Risk Factor Management in Medicare Advantage and Traditional Medicare. [PDF]

Circ Cardiovasc Qual Outcomes
Oseran AS, Aggarwal R, Wadhera RK.
europepmc   +1 more source

Association Between Use of Antihyperlipidemic Agents and Chronic Obstructive Pulmonary Disease in Patients with Hyperlipidemia: A Population-Based Retrospective Cohort Study

, 2020
Lei YF, Lin Hc, Lin Hl, Uang YS, Cheng HW, Wang Lh   +5 more
openalex   +1 more source

Pre‐ and Post‐Interventional Hemodynamic Characterization of the Femoropopliteal Artery Using Vector Flow Imaging in Peripheral Arterial Occlusive Disease

Journal of Ultrasound in Medicine, EarlyView.
Objectives The femoropopliteal (FP) artery is the most frequently revascularized segment in peripheral artery disease (PAD), followed by the iliac segment. Wall shear stress (WSS) is a key local factor implicated in both atherosclerotic plaque formation and restenosis after angioplasty.
Jan Lukas Prüser, Gisela Winkelbauer, Wulf Dieker, Abdulkader Adler, Klaus Amendt, Martin Sigl   +5 more
wiley   +1 more source

Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study. [PDF]

J Am Heart Assoc
Lin CY, Su PL, Kuo CW, Tsai IL, Liu TH, Yang J, Lin CC, Lin SH.   +7 more
europepmc   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source

Risk factors and clinical prediction model for vertebral artery stenosis following radiotherapy for nasopharyngeal carcinoma. [PDF]

J Int Med Res
Zhou J, Ying L, Hui Y, Zhuohua X, Mingjing W, Xiaodong Z.   +5 more
europepmc   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

The association between hypoglycemia and panvascular disease in type 2 diabetes patients: The correlation structure mediated by inflammatory and metabolic abnormalities. [PDF]

Diab Vasc Dis Res
Lan R, Li X, Chen Z, Li Y, Sasmita BR, Hu X, Xu Z, Zuo D, Zuo Z, He A.   +9 more
europepmc   +1 more source

Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available.
Emily Goddard, Aaron Keal, James Hetherington, Sophie Barlow, David Wu, Melany Worbes‐Cerezo, Alexander Litvintchouk   +6 more
wiley   +1 more source